Sarcoma Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The sarcoma drugs market is gaining attraction due to the growing patient assistance programs, new product launches by the big pharmaceutical companies and the growing focus of these companies on R&D which is resulting in the development of novel and advanced therapeutics.

However, the costs of prescription drugs have been rapidly increasing, sometimes at a double-digit rate, for the past seven years. This has led to an increase in the overall healthcare expenditure, making drugs increasingly unobtainable for those with limited means.

According to the Kaiser Family Foundation, in 2018, more than 45 million Americans did not have health coverage, and millions of people were underinsured, with eight out of 10 uninsured people being from salaried families. Among those with health insurance, one out of 10 individuals, who are 65 years old or younger, and one in three persons, above 65 years of age, did not have prescription treatment coverage.

The Patient Assistance Programs (PAPs) emerged in an effort to help patients, who lack health insurance or prescription drug coverage, to get the medication that they require. These programs are generally provided by pharmaceutical corporations, which provide free or low-cost prescription drugs to patients who are suffering from serious diseases. Many states offer medication assistance programs, that vary from one state to another, and cater to the elderly, disabled, or those who are in financial need. Some of the programs are specific for conditions, like cancer.

Pharmaceutical companies donate certain drugs to foundations, which are then provided to the qualifying patients. Several big pharmaceutical companies, such as Pfizer and Eli Lilly, have also started these programs to help uninsured patients who are suffering from chronic diseases. Thus, due to a high number of PAPs, uninsured patients suffering from cancer can also undergo cancer therapies, which is expected to augment the growth of the market.

Scope of the Report

Sarcoma is a type of cancer that can occur in various parts of the body and it is a term used for the large group of cancers that start in the bone and soft tissues.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy to Dominate the Market

Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy work by removing, killing or damaging the cancer cells in a particular area, but chemotherapy works throughout the whole body. This means that chemotherapy can destroy and damage the cancer cells that have spread to the other parts of the body, away from the original tumor. Furthermore, according to the study published in 2015, on the trends in receiving chemotherapy for advanced cancer patients, at the end of life, the proportion of the patients receiving chemotherapy increased successively.

Some of the chemotherapy drugs for sarcoma include doxorubicin, ifosfamide, trabectedin, Temozolomide, etc. As chemotherapy is the primary treatment for sarcomas, it is expected that the market for chemotherapy will be growing in the future.

To understand key trends, Download Sample Report